|
PharmaGap is trying to close the gap between cancer and cure. Lead drug candidate PhG1 is a protein inhibitor that seeks and inactivates a protein present in unusually elevated levels in many types of cancer, including breast, colon, lung, and neuroblastoma. PharmaGap has commenced with animal testing of PhG1. The company also researches drugs to combat multi-drug-resistant conditions, and immune system resistance testing methods in humans and animals. Founded in 1999, PharmaGap is a spin-off of the National Research Council of Canada, a Canadian biological research firm.
|
| | | Contact Information | |
Address: |
100 Sussex Dr.
Ottawa, Ontario K1A 0R6, Canada
| | Phone: | 613-998-3400 | | Fax: | 613-998-3399 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M |
|
|
Key People
| | • |
Chairman:
Roderick M. (Rod) Bryden
| | • |
President and CEO:
Robert C. (Bob) McInnis
| | • |
EVP and COO:
Simon Goulet
|
|
|
